Opiant Pharmaceuticals (NASDAQ: OPNT) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Opiant Pharmaceuticals and Alexion Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opiant Pharmaceuticals 38.89% 5,686.82% 87.49%
Alexion Pharmaceuticals 15.31% 12.47% 8.15%

Valuation & Earnings

This table compares Opiant Pharmaceuticals and Alexion Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Opiant Pharmaceuticals $14.97 million 4.98 $5.99 million $2.54 14.48
Alexion Pharmaceuticals $3.41 billion 9.35 $1.34 billion $2.31 61.87

Alexion Pharmaceuticals has higher revenue and earnings than Opiant Pharmaceuticals. Opiant Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

94.2% of Alexion Pharmaceuticals shares are held by institutional investors. 63.8% of Opiant Pharmaceuticals shares are held by insiders. Comparatively, 4.4% of Alexion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Opiant Pharmaceuticals and Alexion Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opiant Pharmaceuticals 0 0 0 0 N/A
Alexion Pharmaceuticals 0 5 17 1 2.83

Alexion Pharmaceuticals has a consensus price target of $158.41, suggesting a potential upside of 10.84%. Given Alexion Pharmaceuticals’ higher possible upside, analysts plainly believe Alexion Pharmaceuticals is more favorable than Opiant Pharmaceuticals.

Volatility and Risk

Opiant Pharmaceuticals has a beta of -0.75, indicating that its share price is 175% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Opiant Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Receive News & Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.